GRPR and cancer: An interesting new theranostic option for gastrin-releasing peptide receptor (GRPR) positive cancers, is 68Ga- or 177Lu-labelled NeoBOMB1, a DOTA coupled GRPR antagonist with high GRPR affinity and in vivo stability [34].